TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: 1-ranibizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: 2-ranibizumab with laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: 3-laser monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 1-ranibizumab monotherapy, 2-ranibizumab with laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): 2-ranibizumab with laser, 3-laser monotherapy
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: CRVO Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: CRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: CRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: BRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): BRVO standard care, CRVO Observation | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 1 mg dose triamcinolone acetonide, CRVO 1 mg dose triamcinolone acetonide | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 4 mg dose triamcinolone acetonide, CRVO 4 mg dose triamcinolone acetonide
D: Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of bevacizumab | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of ranibizumab (0.5 mg per dose) | Intervention Type: DRUG; Name: Intravitreal injection of bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab (0.5 mg per dose); Assigned to Arm(s): Ranibizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: Ranibizumab driven by disease activity; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Ranibizumab driven by stabilization criteria; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Verteporfin PDT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Verteporfin PDT, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Verteporfin PDT; Assigned to Arm(s): Verteporfin PDT | Intervention Type: DRUG; Name: Sham Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Sham verteporfin PDT; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Arm Label: ranibizumab 0.5mg; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab 0.5mg | Intervention Type: DRUG; Name: ranibizumab 0.5mg; Assigned to Arm(s): ranibizumab 0.5mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: Aflibercept Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Aflibercept | Arm Label: Bevacizumab Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Bevacizumab | Arm Label: Ranibizumab Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Ranibizumab | Intervention Type: BIOLOGICAL; Name: Blood Sample Collection; Assigned to Arm(s): Aflibercept Blood Sample Collection, Bevacizumab Blood Sample Collection, Ranibizumab Blood Sample Collection | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): Aflibercept Blood Sample Collection | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab Blood Sample Collection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab Blood Sample Collection
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: Bevacizumab 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab 1 | Arm Label: Bevacizumab 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab 1; Assigned to Arm(s): Bevacizumab 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab 2
B: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Lucentis (Ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Intervention Type: DRUG; Name: Ranibizumab (Lucentis); Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Novel TB Prevention Regimens for HIV-Infected Adults
Brief Summary: This study compares three different tuberculosis (TB) prevention regimens against the standard regimen of 6 months of isoniazid. It is being conducted in Soweto, South Africa. People who are HIV positive and have a positive tuberculin skin test without signs of active tuberculosis may join.


Options:
A: Arm Label: HIVneg/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVneg/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Arm Label: HIVpos/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVpos/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Intervention Type: DRUG; Name: Isoniazid (INH); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole (TMP/SMX); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Isoniazid Placebo (PL); Assigned to Arm(s): HIVneg/PL, HIVpos/PL
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifapentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rifapentine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: combined fixed dose combination; Assigned to Arm(s): N/A
D: Arm Label: Isoniazid preventive therapy; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Cotrimoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cotrimoxazole, Other: placebo | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): Isoniazid preventive therapy, Placebo | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Antipsychotic Adherence Among Patients With Schizophrenia
Brief Summary: This is a randomized controlled trial examining the effectiveness of a pharmacy-based intervention designed to improve adherence with antipsychotic medications among patients with serious mental illness.


Options:
A: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Unit of use medication packaging, Behavioral: Mailed reminders to patient when medication refills are due, Behavioral: Note to Mental Health Provider when refill is overdue, Procedure: Aligning all prescriptions to fall due on same date | Intervention Type: BEHAVIORAL; Name: Unit of use medication packaging; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Mailed reminders to patient when medication refills are due; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Note to Mental Health Provider when refill is overdue; Assigned to Arm(s): Arm 1 | Intervention Type: PROCEDURE; Name: Aligning all prescriptions to fall due on same date; Assigned to Arm(s): Arm 1
C: Intervention Type: BEHAVIORAL; Name: Peer Mentoring Intervention; Assigned to Arm(s): N/A
D: Arm Label: Adherence counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling | Arm Label: Alarm device; Type: ACTIVE_COMPARATOR; Interventions: Device: Alarm device | Arm Label: Counseling and alarm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling, Device: Alarm device | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adherence counseling; Assigned to Arm(s): Adherence counseling, Counseling and alarm | Intervention Type: DEVICE; Name: Alarm device; Assigned to Arm(s): Alarm device, Counseling and alarm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Study of Olanzapine in Children With Autism
Brief Summary: This is a 12-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 3 to 12 years old. The first six weeks of the study are double-blind and placebo controlled, meaning that patients receive either placebo or olanzapine, and that neither the researchers nor the patients know whether or not they are receiving placebo or olanzapine. In the second six weeks all of the patients receive olanzapine. The purpose in using placebo is that it is otherwise impossible to know how effective the drug is or whether or not the drug causes side effects. Patients treated with placebo can have improvement and can have side effects. In the study patients receive a psychiatric evaluation, physical examination, laboratory tests, and study medication (olanzapine or placebo), free of charge.


Options:
A: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Study of Olanzapine in Children With Autism
Brief Summary: This is a 12-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 3 to 12 years old. The first six weeks of the study are double-blind and placebo controlled, meaning that patients receive either placebo or olanzapine, and that neither the researchers nor the patients know whether or not they are receiving placebo or olanzapine. In the second six weeks all of the patients receive olanzapine. The purpose in using placebo is that it is otherwise impossible to know how effective the drug is or whether or not the drug causes side effects. Patients treated with placebo can have improvement and can have side effects. In the study patients receive a psychiatric evaluation, physical examination, laboratory tests, and study medication (olanzapine or placebo), free of charge.


Options:
A: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D